Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide analog JCC76
Bo Zhong , Rati Lama , Kerri M. Smith , Yan Xu , Bin Su Numerous studies have demonstrated overexpression of cyclo oxygenase 2 (COX 2) in solid malignancies including breast, pros tate, colon, pancreas, nonsmall cell lung, bladder, and endo metrium.
1-5 Prostaglandin 2 (PGE 2 ), the product of COX 2, pro motes tumor invasiveness, angiogenesis, and progression in various cancers. 1, 4, 5 It is therefore reasonable to conclude that inhibition of COX 2 would arrest carcinogenesis and thus, (1) prevent cancer development and (2) regress cancer once developed. Corresponding to these observations and theory, epidemiological, clinical, and pre clinical studies provide compelling evidence that the use of COX 2 selective inhibitors may reduce the incidence of mammary cancer and colorectal cancer. 6-9 Theoretically, COX 2 inhibitors achieve all the anti cancer or cancer preventive activity by targeting COX 2. However, these small molecules may also block other cellular machineries to affect the cancer cell function, which may lead to cell growth inhibition, apoptosis or necrosis. With the extensive studies of COX 2 inhibitors about their anti cancer or cancer pre vention activity, molecular targets of the drugs beyond COX 2 seems play a very important role for their antineoplastic activity. Many researchers even suggested that COX independent effects might be fully responsible for the anti cancer properties of some COX 2 inhibitors. 10,11 The phenomenon is more like an off target ef fect, which also underscores the needs to explore targets beyond COX 2, especially in view of emerging toxicity of the COX 2 inhib itors. Developing nonCOX 2 inhibitory analogs as new anti cancer drug based on COX 2 inhibitors as lead compound is feasible and practicable. In fact, this principle has been successfully applied in the discovery of some new anti cancer drugs. For instance, COX 2 inhibitor Celecoxib weakly inhibits PDK 1 kinase in prostate cancer cells. It has been used as a molecular scaffold to develop more po tent PDK 1 inhibitors (no COX 2 inhibitory activity) which block PI3 K/AKt pathway. The generated new analog, such as OSU 03012 is 20 fold more active than Celecoxib to inhibit tumor cell proliferation and to induce cell apoptosis, which is currently in a phase I clinical trial. 12,13 Nimesulide (4 nitro 2 phenoxymethane sulfoanilide) is a nonsteroidal anti inflammatory drug with a pref erential COX 2 inhibitory activity and is available in some Asian and European countries since 1985. Studies suggest that nimesulide could induce apoptosis in liver and lung cancer cells; it also suppressed the development of 2 amino 1 methyl 6 phenylimi dazo[4,5 b]pyridine (PhIP) induced mammary gland carcinogene sis in rats. [14] [15] [16] [17] NonCOX 2 active nimesulide derivatives have been synthesized. Some analogs were much more active than nimesulide in suppressing breast cancer cell growth. 18 Interest ingly, the most potent analog JCC76 was selectively potent in Her2 overexpressed breast cancer cells. 19, 20 Both in vitro and in vivo anticancer properties of JCC76 make it a potential new drug candidate or drug lead for Her2 overexpressed breast cancer.
To rational design more potent analogs of JCC76 based on its binding pocket and optimize the structure activity relationship (SAR), it is a prerequisite to identify the specific molecular target(s) of JCC76. Although JCC76 exhibited good selectivity to Her2 over expressed breast cancer cells, it did not show any significant block Post-print standardized by MSL Academic Endeavors, the imprint of Michael Schwartz Library at Cleveland State University, 2017.
